GS24-B025
/ GeneScience
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 13, 2025
GS24-B025, a highly differentiated CDH17- and CEA-directed bispecific antibody-drug conjugate (bsADC), for the treatment of colorectal cancer
(AACR-NCI-EORTC 2025)
- "These preclinical data suggest the potential of GS24-B025 as an effective treatment option for CRC patients and support its further evaluation in IND-enabling studies."
Colorectal Cancer • Oncology • Solid Tumor • CDH17 • CEACAM5
1 to 1
Of
1
Go to page
1